Background

After a clinical review of the Pharmacy First Clinical Pathways, several changes were introduced including additional gateway points.

This Roadmap Item is to provide the latest version of the Clinical Pathways to allow Suppliers the opportunity to review the proposed changes.

Few key points to be noted in the context of this change,

• There are no change to the GP Connect Update Record data fields, merely new clinical guidance/ steps in the existing flow.

• The PDF alternative to GP Connect Update Record does not require any formatting changes to the PDF.

• The changes do not introduce any new fields to the BSA Claim format. The tests with BSA will be to ensure the data flows at the right gateway points.

Suppliers should take note of the following related Roadmap Items:

• RM275 Update Pharmacy Contraception Service to include Oral Emergency Contraception

• RM276 Update Pharmacy Contraception Service to include a new medication for Oral Contraception

Outline Plan

Supplier Solutions must be fully compliant with the uplifts to the Clinical Pathways v2.5 by the Effective Date.

Summary of Change

Full Specification

N/A

Assurance Approach

To be fully assured on the change, Suppliers are required to complete the following Assurance steps:

1. Supplier’s Clinical Safety Officer (CSO) responsibilities:

   1. Supplier’s CSO must attend a meeting with NHSE to confirm understanding of their clinical safety responsibilities.

   2. Supplier’s CSO is required to participate in all Assurance calls.

2. Supplier’s internal testing requirements:

   1. The Supplier must complete Product testing, Regression testing and an internal Clinical Review.

   2. Supplier test scenarios are to cover all elements of the Supplier Solution that require changes. Supplier test reports to be shared with NHSE once Supplier testing is successfully concluded.

   3. The Supplier must provide written confirmation from their CSO stating that all internal tests have been completed. NHSE will accept email as written confirmation.

3. End to End testing with BSA:

   1. The Supplier must complete End to End testing with the BSA. The BSA Test environment will be available for the testing.

   2. Prior to assurance, the BSA will contact each Supplier to check that they have correct IP address ranges allowlisted in their Test environment so that test messages can be sent/received successfully.

   3. The BSA will provide evidence (screen shots or report) to NHSE to demonstrate that payment data reconciles correctly between the Supplier Solution (Sender) and the BSA API (Receiver).

4. Clinical Assurance:

   1. Clinical Assurance will be carried out as a Live Witness Test. NHSE will schedule a Live Witness Test with the Supplier, NHSE Clinical Team and Policy colleagues.

   2. The Supplier must demonstrate their Solution in the Test environment, specifically showing access to v2.5 of the Pharmacy First Clinical Pathway documents.

   3. The Supplier must walk through workflows for various test scenarios as outlined in the Test Packs using a pass/fail approach. Test Packs will be provided by NHSE once development is complete and Assurance dates are arranged. NHSE’s test scenarios are provided for reference.

   4. The Supplier must be prepared to test additional items that may arise during the session that may not necessarily be called out in the Test Packs. e.g. functionality that is likely to impact clinical safety.

5. Smoke Testing:

   1. The Supplier must complete Smoke testing in the Live environment, in collaboration with NHSE, by rerunning the earlier tests using test patients.

Note: Suppliers can contact their Supplier Manager for more information on the Assurance approach outlined above.